Fred Butler
Hematology & Oncology · Indianapolis, INNPI 1174592166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 15.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $991 and has fallen 97.9% since, to $21 in 2023. That places this record below the midpoint for hematology & oncology clinicians in IN, where the typical reported total is $3,829.
Across 99 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$240
- Genentech USA, Inc.$185
- Johnson & Johnson$180
- E.r. Squibb & Sons, L.L.C.$155
- Sanofi$106
- AstraZeneca$100
- plus $588 from 19 others
Across 15 payments — averaging $12,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$60K
- Morphosys AG$44K
- Astrazeneca UK Limited$37K
- EMD Serono, Inc.$31K
- Incyte Corporation$13K
What the payments were for
- Food & beverage$1,553100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 21 | $240 |
| Genentech USA, Inc. | 12 | $185 |
| Johnson & Johnson(2 entities) | 11 | $180 |
| E.r. Squibb & Sons, L.L.C. | 8 | $155 |
| Sanofi | 6 | $106 |
| AstraZeneca | 4 | $100 |
| Pfizer | 5 | $70 |
| Novartis | 4 | $65 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $60 |
| Merck | 3 | $46 |
| Bayer | 2 | $42 |
| Bristol Myers Squibb | 2 | $40 |
| Incyte Corporation | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Coherus Oncology, Inc. | 2 | $31 |
| Exelixis Inc. | 2 | $25 |
| Tesaro, Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Seagen Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $11 |
How this compares
$1,553 in reported general payments places this provider in the 30th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.